Arena Pharmaceuticals Announces Merck Discontinues Development Of Investigational Niacin Receptor Agonist Program For Atherosclerosis
- 7:41 AM — Dec 29 —
- Source: PharmaInfo.net
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Read More
Weight Loss Drug To Boost Arena Pharma’s Future( ARNA)
- 1:24 PM — Dec 28 —
- Source: Benzinga
Capital Group LLC ( CRT ) has affirmed its 'buy' rating on Arena Pharmaceuticals (NASDAQ: ARNA ) with a target price of $8, backed by its submission of an NDA (New Drug Application) for Lorcaserin, a weight loss drug. Read More
Arna Bontemps Museum celebrating Kwanzaa today, Dec. 27, and Tuesday, Dec. 29
- 3:52 AM — Dec 27 —
- Source: The Town Talk - Alexandria LA
The Arna Bontemps Museum is celebrating Kwanzaa from 6 p.m. to 8 p.m. today, Dec. 27, at the Arna Bontemps Museum and from 6 pm. to 8 p.m. Read More
Jefferies & Co Initiates Coverage on Biotechnology and Drugs Stocks
- 10:14 AM — Dec 17 —
- Source: StreetInsider.com
Jefferies & Co initiates coverage on VIVUS (Nasdaq: VVUS ) with a Hold. Price target $9. Read More
Naperville North High School 2009 Action Gallery
- 3:44 AM — Dec 17 —
- Source: Daily Herald - Arlington Heights IL
ROUND 1: Naperville's Arnas Gintautas reacts to a loss at Fremd. Read More
UKB: A subordinated loan of LTL 50 million has been provided to AB Ukio bankas
- 11:20 AM — Dec 15 —
- Source: HEX Tallinn
Arnas Žalys, Head of Finance Division, +370 37 301 440. Read More
